M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-05-12
DOI
10.3389/fonc.2020.00674
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
- (2020) Zhuo-Xun Wu et al. Cancers
- Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications
- (2019) Yu Toyoda et al. Frontiers in Pharmacology
- Avapritinib, a selective inhibitor of KIT and PDGFRα reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines
- (2019) Chung-Pu Wu et al. MOLECULAR PHARMACEUTICS
- Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: ECOG-ACRIN 5508
- (2019) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
- (2019) Ning Ji et al. Frontiers in Oncology
- Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells
- (2019) Zhuo-Xun Wu et al. BIOCHEMICAL PHARMACOLOGY
- Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance
- (2019) Jing-Quan Wang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Randomized Phase II Trial of Adjuvant Chemotherapy with Docetaxel plus Cisplatin versus Paclitaxel plus Carboplatin in Patients with Completely Resected Non-Small Cell Lung Cancer: TORG 0503
- (2019) Kaoru Kubota et al. LUNG CANCER
- Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics
- (2019) Rayana L. Bighetti-Trevisan et al. Stem Cells International
- The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
- (2019) Chung-Pu Wu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2
- (2019) Bin Ke et al. MEDIATORS OF INFLAMMATION
- Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
- (2019) Hannah C. Wise et al. Scientific Reports
- Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro
- (2018) Ales Sorf et al. BIOCHEMICAL PHARMACOLOGY
- Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo
- (2018) Guan-Nan Zhang et al. CANCER LETTERS
- SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines
- (2018) Chung-Pu Wu et al. CANCER LETTERS
- The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells GrownIn Vitroand as Orthotopic Xenografts
- (2018) Cindy R. Timme et al. MOLECULAR CANCER THERAPEUTICS
- Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data?
- (2018) David Ramírez et al. MOLECULES
- Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
- (2018) Scott M. Jackson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
- (2018) Scott M. Jackson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 in vitro and in vivo
- (2018) Zhiqiang Zhang et al. Acta Pharmaceutica Sinica B
- PCI29732, a Bruton’s Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells
- (2018) Chunlei Ge et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance
- (2018) Ning Ji et al. BIOCHEMICAL PHARMACOLOGY
- Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells
- (2018) Ning Ji et al. CANCER LETTERS
- Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
- (2018) Wei Zhang et al. Frontiers in Pharmacology
- The epigallocatechin gallate derivative Y6 reverses drug resistance mediated by the ABCB1 transporter both in vitro and in vivo
- (2018) Yan Wen et al. Acta Pharmaceutica Sinica B
- Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer
- (2018) Yun-Kai Zhang et al. CANCER LETTERS
- Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib
- (2017) Guan-Nan Zhang et al. PHARMACOLOGICAL RESEARCH
- Abstract 1658: M3814, a novel investigational DNA-PK inhibitor: enhancing the effect of fractionated radiotherapy leading to complete regression of tumors in mice
- (2016) Frank T. Zenke et al. CANCER RESEARCH
- M3814, a DNA-dependent Protein Kinase Inhibitor (DNA-PKi), Potentiates the Effect of Ionizing Radiation (IR) in Xenotransplanted Tumors in Nude Mice
- (2016) L. Damstrup et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population
- (2016) J Sun et al. PHARMACOGENOMICS JOURNAL
- Molecular mechanisms of drug resistance and its reversal in cancer
- (2015) Melis Kartal-Yandim et al. CRITICAL REVIEWS IN BIOTECHNOLOGY
- Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
- (2014) Qingcheng Mao et al. AAPS Journal
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Multidrug Resistance and Cancer Stem Cells in Neuroblastoma and Hepatoblastoma
- (2013) Anna Alisi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Impact ofABCG2polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
- (2011) Clara Lemos et al. PHARMACOGENOMICS
- The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas
- (2010) Feng Li et al. MEDICAL ONCOLOGY
- Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design
- (2008) N. Giri et al. DRUG METABOLISM AND DISPOSITION
- MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer
- (2008) T. Oguri et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started